Stocks Health care RLYB

NASDAQ · Health care

Rallybio Corp (RLYB)

Rallybio Corp brought in $646K of revenue over the twelve months to June 30, 2026, down 15.1% from a year earlier. Net income was $45.6M, a net margin of 7,051.2%. At June 30, 2026 it held $92.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Watch RLYB in 60 seconds

Follow RLYB

Free, no password. An email when RLYB files with the SEC.

Key facts about Rallybio Corp

Net worth

Rallybio Corp has a market value (market cap) of $82.9M at the latest share price, and shareholders' equity of $94.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was $858K (+34.9% year on year), with a net loss of $9M.

Cash flow

In fiscal 2025 operations used $29.8M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

Rallybio Corp's next report was expected around November 5, 2026 and is not on file with the SEC yet.

What Rallybio Corp does

Rallybio Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RLYB.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where RLYB ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Rallybio Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. October 5, 2026
   Merger registration (amended) S-4/A
2. September 16, 2026
   Merger registration (amended) S-4/A
3. September 9, 2026
   Executive or director change 8-K
4. August 26, 2026
   Merger registration (amended) S-4/A
5. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
6. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
7. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
8. August 6, 2026
   Passive stake changed SCHEDULE 13G/A
9. August 6, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS $7.53 versus -$0.22.
10. August 4, 2026
    Passive stake changed SCHEDULE 13G/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 1, 2026. Insider transactions on SEC

Insider trades

What the people running Rallybio Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 4 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns RLYB

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Cormorant Asset Management, LP 0% (August 14, 2026); Balyasny Asset Management L.P. 0% (August 14, 2026); Nantahala Capital Management, LLC 3.56% (August 14, 2026); Laurion Capital Management LP 0% (August 4, 2026); 5AM Ventures V, L.P. 0% (May 6, 2026).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 37 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 958,240 shares in total, about $15M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about RLYB

What does Rallybio Corp do?

Rallybio Corp is a company in the Health care sector, listed on NASDAQ as RLYB. Its shares trade on NASDAQ under the ticker RLYB.

What is Rallybio Corp's net worth?

Rallybio Corp has a market value (market cap) of $82.9M at the latest share price, and shareholders' equity of $94.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Rallybio Corp profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $45.6M on revenue of $646K, a net margin of 7,051.2%.

How much revenue does Rallybio Corp make?

Over the twelve months to June 30, 2026 Rallybio Corp reported revenue of $646K. That is 15.1% less than a year earlier.

When did Rallybio Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the merger registration (amended) from October 5, 2026.

When is Rallybio Corp's next earnings report?

Rallybio Corp's next report was expected around November 5, 2026 and is not on file with the SEC yet.

Similar companies

Compare RLYB with

Compare RLYB with any company

Follow RLYB

Get an email when Rallybio Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow RLYB

Free, no password. An email when RLYB files with the SEC.

Where the numbers come from

Financial figures are the values Rallybio Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.